Pyro wrote:They’re not going to have any secrets your oncologist doesn’t know about, save your money.
Rock_Robster wrote:I find these sorts of things fascinating too. However the question my oncologist always asks me when I enquire about 3rd party testing - what are you going to do differently because of this information?
His argument is that information should be used to guide treatment, and my treatment will be done according to the evidence-based protocol for my specific case (to which I, gratefully, have been responding well), with his additional judgement applied when necessary.
If you were facing a decision point (e.g. to do chemo or not, or which type of targeted therapy to include) or were running out of treatment options, then you could ask your onc whether there is additional information which could help make a better decision. However if this is just a ‘curiosity’ test, then he usually tells me to save my money for other things that can help me now.
TinaFish wrote:... "Ok, I'll talk to her on Wednesday when I go in for chemo."
That's three days from now. Good luck to me.
" RAS Mutational Analysis
The presence of a KRAS mutation has been shown to be associated with lack of clinical response to therapies
targeted at EGFR, such as cetuximab and panitumumab. While clinical guidelines for KRAS mutational analysis
are evolving, current provisional recommendations from the American Society of Clinical Oncology are that all
patients with stage IV colorectal carcinoma who are candidates for anti-EGFR antibody therapy should have their
tumor tested for KRAS mutations. Anti-EGFR antibody therapy is not recommended for patients whose tumors
show mutations in KRAS codon 12, 13, or 61, but data on codon 146 are currently insufficient. A recent study has
shown that NRAS mutation, like KRAS mutation, has influence on response to anti-EGFR therapy. Although
more studies are needed, these findings may lead to broad KRAS and NRAS panels to include codons 12, 13, 61,
and 146 of both genes."
Source: College of American Pathologists
boxhill wrote:... You may need to make it clear to your doctor whether you are willing to pay for it out of pocket in order for things to proceed....
According to Qiagen, the Therascreen KRAS RGQ Kit (which includes confirmation of DNA integrity and the detection of seven KRAS mutations) has a unit price ranging between C$170 to $200 (Frederick S. Jones, Qiagen Inc., Germantown (MD): personal communication, 2014 Jan 13). A Canadian cost-effectiveness study estimated that the cost of KRAS mutation testing was between $150 and $500 (in 2009 Canadian dollars)
TinaFish wrote:When I met with my oncologist a couple of weeks ago, I asked her if we could do genomic testing on leftover tissue from my biopsy. She said yes. But as of two days ago, the testing still hadn't been ordered. I don't know whether genomic testing is routine.
Users browsing this forum: No registered users and 48 guests